BCMA CAR T 细胞：曲折通向成功之路。
BCMA CAR T cells: the winding path to success.
出版信息
J Clin Invest. 2019 Apr 29;129(6):2175-2177. doi: 10.1172/JCI128372.
Abstract
Chimeric antigen receptor (CAR) T cells have been shown to successfully treat some hematopoietic malignancies. Recognition of a relevant target on malignant cells and the proper costimulatory molecule are essential for CAR T cell efficacy. In this issue of the JCI, Cohen et al. conducted an early phase trial to evaluate B cell maturation antigen-targeting (BCMA-targeting) CAR T cells in patients with refractory multiple myeloma. Patients who received the highest dose of BCMA-targeting CAR T cells in combination with lymphodepletion had the greatest response. The results of the study provide further support for the use of BCMA-targeting CAR T cells for myeloma, and reiterate the importance of space and cell dose for CAR T cell success.
摘要
嵌合抗原受体 (CAR) T 细胞已被证明可成功治疗某些血液系统恶性肿瘤。CAR T 细胞的疗效取决于对恶性细胞上相关靶标的识别和适当的共刺激分子。在本期 JCI 中，Cohen 等人进行了一项早期临床试验，以评估针对 B 细胞成熟抗原（BCMA）的 CAR T 细胞在难治性多发性骨髓瘤患者中的作用。接受最高剂量的 BCMA 靶向 CAR T 细胞联合淋巴细胞耗竭治疗的患者反应最大。该研究结果进一步支持了使用 BCMA 靶向 CAR T 细胞治疗骨髓瘤，并重申了 CAR T 细胞成功的空间和细胞剂量的重要性。
相似文献
1
BCMA CAR T cells: the winding path to success.BCMA CAR T 细胞：曲折通向成功之路。
J Clin Invest. 2019 Apr 29;129(6):2175-2177. doi: 10.1172/JCI128372.
2
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.γ-分泌酶抑制剂联合 BCMA 嵌合抗原受体 T 细胞免疫疗法治疗复发或难治性多发性骨髓瘤患者的 1 期、首次人体试验。
Lancet Oncol. 2023 Jul;24(7):811-822. doi: 10.1016/S1470-2045(23)00246-2.
3
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原表达的血液系统恶性肿瘤。
Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
4
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.同种异体嵌合抗原受体 T 细胞靶向 BCMA 治疗多发性骨髓瘤的临床前评估。
Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8.
5
Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.第五代嵌合抗原受体 T 细胞靶向多发性骨髓瘤中的 B 细胞成熟抗原增强抗肿瘤疗效、增殖能力和 T 细胞耗竭缓解作用。
Biomed Pharmacother. 2023 Dec;168:115691. doi: 10.1016/j.biopha.2023.115691. Epub 2023 Oct 14.
6
Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.BCMA 靶向 CAR-T 免疫疗法治疗多发性骨髓瘤和复发性/难治性多发性骨髓瘤概述。
Scand J Immunol. 2020 Aug;92(2):e12910. doi: 10.1111/sji.12910. Epub 2020 Jun 17.
7
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.靶向多发性骨髓瘤中的 B 细胞成熟抗原（BCMA）：基于 BCMA 的免疫疗法的潜在用途。
Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821. eCollection 2018.
8
Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.双表位 CAR T 靶向 B 细胞成熟抗原治疗复发/难治性多发性骨髓瘤的探索性试验。
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551. doi: 10.1073/pnas.1819745116. Epub 2019 Apr 15.
9
CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.嵌合抗原受体 T 细胞增强对 B 细胞成熟抗原的敏感性，用于靶向治疗 B 细胞非霍奇金淋巴瘤和多发性骨髓瘤。
Mol Ther. 2018 Aug 1;26(8):1906-1920. doi: 10.1016/j.ymthe.2018.06.012. Epub 2018 Jun 18.
10
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.B 细胞成熟抗原是多发性骨髓瘤过继性 T 细胞治疗的一个有前途的靶点。
Clin Cancer Res. 2013 Apr 15;19(8):2048-60. doi: 10.1158/1078-0432.CCR-12-2422. Epub 2013 Jan 23.
引用本文的文献
1
First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comorbidities: a case report.一线抗BCMA嵌合抗原受体T细胞疗法治疗一名患有双克隆丙种球蛋白病和巨大浆细胞肿瘤的多发性骨髓瘤且合并多种疾病的脆弱患者：一例报告
Front Immunol. 2025 Apr 16;16:1564774. doi: 10.3389/fimmu.2025.1564774. eCollection 2025.
2
Advancing to the era of cancer immunotherapy.迈入癌症免疫治疗时代。
Cancer Commun (Lond). 2021 Sep;41(9):803-829. doi: 10.1002/cac2.12178. Epub 2021 Jun 24.
3
Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019.测量 1990 年至 2019 年全球、区域和国家多发性骨髓瘤的负担。
BMC Cancer. 2021 May 25;21(1):606. doi: 10.1186/s12885-021-08280-y.
4
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.多发性骨髓瘤的成功治疗是否更近了一步？CAR-T 细胞是一个值得乐观的好理由。
Stem Cell Res Ther. 2021 Mar 29;12(1):217. doi: 10.1186/s13287-021-02283-z.
5
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.免疫调节药物来那度胺和泊马度胺可增强AMG 701在多发性骨髓瘤临床前模型中的效力。
Blood Adv. 2020 Sep 8;4(17):4195-4207. doi: 10.1182/bloodadvances.2020002524.
6
Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.为多发性骨髓瘤的成功治疗铺平道路：嵌合抗原受体 T 细胞疗法。
Cells. 2020 Apr 16;9(4):983. doi: 10.3390/cells9040983.
7
Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.嵌合抗原受体修饰 T 细胞疗法在多发性骨髓瘤中的应用：超越 B 细胞成熟抗原。
Front Immunol. 2019 Jul 16;10:1613. doi: 10.3389/fimmu.2019.01613. eCollection 2019.
本文引用的文献
1
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.B 细胞成熟抗原特异性嵌合抗原受体 T 细胞在多发性骨髓瘤中具有临床活性。
J Clin Invest. 2019 Mar 21;129(6):2210-2221. doi: 10.1172/JCI126397.
2
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.输注前多能抗 CD19 嵌合抗原受体 T 细胞与 NHL 的临床结果相关。
Blood. 2018 Aug 23;132(8):804-814. doi: 10.1182/blood-2018-01-828343. Epub 2018 Jun 12.
3
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
4
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.使用特定比例的CD8+和CD4+ CD19特异性嵌合抗原受体修饰的T细胞对非霍奇金淋巴瘤进行免疫治疗。
Sci Transl Med. 2016 Sep 7;8(355):355ra116. doi: 10.1126/scitranslmed.aaf8621.
5
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.表达抗B细胞成熟抗原嵌合抗原受体的T细胞可使多发性骨髓瘤缓解。
Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.
6
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.转移性黑色素瘤患者肿瘤浸润淋巴细胞过继性转移前淋巴细胞清除强度的随机前瞻性评估
J Clin Oncol. 2016 Jul 10;34(20):2389-97. doi: 10.1200/JCO.2016.66.7220. Epub 2016 May 23.
7
Chimeric antigen receptor T cells for sustained remissions in leukemia.用于白血病持续缓解的嵌合抗原受体T细胞。
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
8
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.嵌合抗原受体修饰的 T 细胞治疗急性淋巴细胞白血病。
N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25.
9
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.转移性黑色素瘤患者的过继性细胞疗法：强化清髓性放化疗预处理方案的评估
J Clin Oncol. 2008 Nov 10;26(32):5233-9. doi: 10.1200/JCO.2008.16.5449. Epub 2008 Sep 22.
10
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.多发性骨髓瘤患者的移植物抗肿瘤反应与对浆细胞膜受体BCMA的抗体反应相关。
Blood. 2005 May 15;105(10):3945-50. doi: 10.1182/blood-2004-11-4463. Epub 2005 Feb 3.
Zotero 插件